WEST CHESTER, Ohio, May 10 /PRNewswire-FirstCall/ -- AtriCure, Inc. , a medical device company focused on developing, manufacturing and selling innovative surgical devices, today announced record revenues for the first quarter ended March 31, 2007.
“We are pleased with our first quarter financial results and extremely encouraged regarding our achievement of a series of product and regulatory milestones, including the full commercial release of our open Isolator Synergy(TM) ablation system,” said David Drachman, President and Chief Executive Officer. “Additional achievements included a FDA regulatory filing in support of a cardiac ablation indication for our Isolator(R) bipolar ablation clamps and our FDA filing to support our left atrial appendage occlusion clip. Importantly, we filed an extension for a new arm of our minimally invasive clinical trial, RESTORE-SR IIB, designed to investigate our endoscopic Isolator Synergy(TM) system and our multifunctional bipolar Pen for treating patients with persistent and permanent atrial fibrillation. We are confident that the achievement of these major milestones will facilitate the increased adoption of our open and MIS products.”
First Quarter 2007 Financial Results
First quarter 2007 consolidated revenues were $10.8 million, a 24.5% year-over-year increase compared to revenues of $8.6 million for the first quarter of 2006 and a 1.4% sequential increase compared to revenues of $10.6 million for the fourth quarter of 2006. First quarter 2007 revenues from domestic products used in open procedures were $6.6 million, a 17.8% year-over-year increase compared to revenues of $5.6 million for the first quarter of 2006 and a 3.2% sequential increase. Revenues from domestic minimally invasive products were $3.0 million, a 32.5% year-over-year increase compared to revenues of $2.2 million for the first quarter of 2006 and a 9.8% sequential decrease. International revenues were $1.2 million, a 47.4% year-over-year increase compared to revenues of $0.8 million for the first quarter of 2006 and a 28.4% sequential increase.
First quarter 2007 gross profit was $8.5 million, resulting in a gross margin of 79.4%, compared to a gross margin of 81.5% for the first quarter of 2006 and 77.8% for the fourth quarter of 2006. The change in gross margin as compared to the first quarter of 2006 was primarily due to the introduction of new products, which initially carry a higher product cost. The change in gross margin as compared to the fourth quarter of 2006 was primarily due to a fourth quarter inventory valuation charge of $0.2 million.
Research and development expenses for the first quarter of 2007 were $3.1 million, a 7.5% increase over the first quarter of 2006 and a decrease of 2.4% as compared to the fourth quarter of 2006. Selling, general and administrative expenses, or SG&A, were $10.3 million, a 37.2% increase as compared to $7.5 million in the first quarter of 2006 and an 8.3% increase over $9.5 million in the fourth quarter of 2006. The increase in SG&A as compared to the first quarter of 2006 was primarily due to increased selling and marketing expenses, increased stock-based compensation expense and $0.3 million in costs associated with the proposed settlement of a legal dispute with a former European distributor.
Operating loss for the first quarter of 2007 was $4.9 million as compared to $3.4 million for the first quarter of 2006 and $4.5 million for the fourth quarter of 2006. Interest and other income for the first quarter of 2007 included $0.3 million of grant income. Loss per share was $0.35 for the first quarter of 2007 as compared to $0.26 for the first quarter of 2006 and $0.35 for the fourth quarter of 2006. First quarter 2007 results include stock- based compensation expense of $0.6 million, or $0.05 per share, including a valuation adjustment of $0.2 million, or $0.02 per share. First quarter 2006 results included $0.2 million of stock-based compensation expense, or $0.01 per share.
Cash, cash equivalents and investments at March 31, 2007 were $16.0 million. Cash used in operations was $3.0 million for the first quarter of 2007 as compared to $3.8 million for the first quarter of 2006.
Financial Guidance
The Company is confirming its full year 2007 guidance of $48 to $50 million for revenues and an expected net loss per share between $0.95 and $1.05. For the second quarter of 2007, the Company expects revenues to be between $11.6 and $12.3 million.
Conference Call
AtriCure will host a Web cast and conference call at 11:00 am EDT on May 10, 2007 to discuss first quarter 2007 results. A live Web cast of the conference call will be available online from the investor relations page of AtriCure’s corporate Web site at www.atricure.com. The dial-in numbers are (866) 831-5605 for domestic callers, and (617) 213-8851 for international callers. The reservation number for both is 40584114.
A recording of the conference call will remain available on AtriCure’s Web site through June 9, 2007. A telephonic replay of the call will be available until June 9, 2007. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 24348175.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices designed to create precise lesions, or scars, in soft and cardiac tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation clamps as a treatment alternative during open- heart surgical procedures to create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiothoracic surgeons have described the AtriCure Isolator(R) clamps as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system, including the new Isolator Synergy(TM) ablation clamps, for the ablation, or destruction, of soft tissues in general and non-cardiac related surgical procedures, but to date has not cleared or approved the system for cardiac use or for the treatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Pen for the ablation of cardiac tissue and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias, but the multifunctional bipolar Pen has not been approved for the treatment of AF.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure’s products. Forward-looking statements are based on AtriCure’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure’s products, AtriCure’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure’s products, competition from existing and new products and procedures or AtriCure’s ability to effectively react to other risks and uncertainties described from time to time in AtriCure’s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation (including the purported class action lawsuit) or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
ATRICURE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended March 31, 2007 2006 Revenues $10,750,770 $8,636,808 Cost of revenues 2,210,495 1,599,741 Gross profit 8,540,275 7,037,067 Operating expenses: Research and development expenses 3,129,278 2,910,493 Selling, general and administrative expenses 10,283,187 7,496,098 Total operating expenses 13,412,465 10,406,591 Loss from operations (4,872,190) (3,369,524) Other income (expense): Interest income, net 149,923 279,753 Grant income 338,143 - Foreign currency transaction gain 81,703 - Net loss $(4,302,421) $(3,089,771) Basic and diluted loss per share $(0.35) $(0.26) Weighted average shares outstanding: Basic and diluted 12,298,424 12,096,200 ATRICURE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) March 31, December 31, 2007 2006 Assets Current assets: Cash and cash equivalents $13,186,141 $14,890,383 Short-term investments 2,797,820 4,598,032 Accounts receivable, net 6,264,462 6,562,341 Inventories, net 4,115,658 3,389,401 Other current assets 1,371,575 1,247,738 Total current assets 27,735,656 30,687,895 Property and equipment, net 3,767,652 3,643,069 Intangible assets 719,278 772,778 Goodwill 3,840,837 3,840,837 Other assets 168,896 183,486 Total assets $36,232,319 $39,128,065 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued liabilities $7,810,909 $7,265,424 Current maturities of long-term debt and capital leases 399,406 391,460 Total current liabilities 8,210,315 7,656,884 Long-term debt and capital leases 589,662 692,544 Other liabilities 323,438 84,375 Total liabilities 9,123,415 8,433,803 Stockholders’ equity: Common stock 12,304 12,189 Additional paid-in capital 87,414,130 86,646,064 Other comprehensive income 39,555 90,673 Accumulated deficit (60,357,085) (56,054,664) Total stockholders’ equity 27,108,904 30,694,262 Total liabilities and stockholders’ equity $36,232,319 $39,128,065 ATRICURE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Three Months Ended March 31, 2007 2006 Cash flows from operating activities: Net loss $(4,302,421) $(3,089,771) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 502,585 473,665 Loss (gain) on disposal of equipment 3,856 (20,000) Provision for losses on accounts receivable (66,624) 65,074 Share-based compensation expense 641,940 150,268 Changes in assets and liabilities: Accounts receivable 364,503 (670,523) Inventories, net (726,258) (573,386) Other current assets (123,836) 119,181 Accounts payable and accrued liabilities 506,266 (250,824) Other non-current assets and liabilities 241,420 30,870 Net cash used in operating activities (2,958,569) (3,765,446) Cash flows from investing activities: Purchases of property & equipment, net (526,071) (193,389) Purchases of available-for-sale securities (6,762) (353,929) Maturities of available-for-sale securities 1,808,000 - Net cash provided by (used in) investing activities 1,275,167 (547,318) Cash flows from financing activities: Payments on long-term debt and capital leases (94,935) (91,059) Proceeds from stock option exercises 126,241 29,150 Net cash provided by (used in) financing activities 31,306 (61,909) Effect of exchange rate changes on cash (52,146) - Net decrease in cash and cash equivalents (1,704,242) (4,374,673) Cash and cash equivalents - beginning of period 14,890,383 27,432,948 Cash and cash equivalents - end of period $13,186,141 $23,058,275 Contacts: AtriCure, Inc. Julie Piton Vice President and Chief Financial Officer (513) 755-4561 jpiton@atricure.com The Ruth Group Nick Laudico (investors) (646) 536-7030 nlaudico@theruthgroup.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com
AtriCure
CONTACT: Julie Piton, Vice President and Chief Financial Officer,AtriCure, Inc., +1-513-755-4561, jpiton@atricure.com; investors, NickLaudico, +1-646-536-7030, nlaudico@theruthgroup.com, or media, Jason Rando,+1-646-536-7025, jrando@theruthgroup.com, both of The Ruth Group
Web site: http://www.atricure.com//
